Want to see SEED full AI Analyst Report?
SEED Stock Chart & Stats
$1.00
-$0.01(-0.99%)
At close: 4:00 PM EDT
$1.00
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$0.91 - $2.49
Previous CloseN/A
Volume1.83K
Average Volume (3M)2.25M
Market Cap
$12.14M
Enterprise Value$14.71
Total Cash (Recent Filing)$13.37M
Total Debt (Recent Filing)$29.12M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Jan 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding12,144,586
10 Day Avg. Volume6,011,928
30 Day Avg. Volume2,246,586
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.76
Price to Sales (P/S)0.71
P/FCF Ratio-1.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Large, Deep Breeding Pipeline And AI‑enabled Germplasm ResourcesA materially deep breeding pipeline and AI‑assisted access to 200k+ germplasm entries create durable product optionality. Over time this increases probability of commercially viable varieties, supports licensing and trait monetization, and strengthens technological barriers to entry.
Strengthened Biotech Credentials And Commercialization ReadinessHolding biosafety certification, gene‑editing platforms and restored processing infrastructure is a lasting advantage for bringing GMO/gene‑edited varieties to market. These capabilities shorten time to commercialization and enable new revenue streams beyond seed sales (e.g., breeding services, partnerships).
Rebuilt Commercial Organization And Targeted Promotion ProgramA materially rebuilt salesforce and regionally targeted promotion program represent durable commercial capacity. Sustained investment in distribution and dealer KPIs improves sell‑through odds for new varieties and supports scaling revenues if product efficacy and approvals align.
Bears Say
Stressed Balance Sheet: Negative Equity And Higher DebtPersistent negative equity and a marked debt increase materially reduce financial flexibility. This structure raises refinancing and dilution risk, limits capacity for R&D and commercial investments without external funding, and makes the company vulnerable to adverse funding conditions over the medium term.
Weak And Inconsistent Cash Generation; Ongoing Free‑cash‑flow BurnSustained negative operating cash flow and recurring free‑cash‑flow deficits indicate the business is not self‑funding growth. Reliance on external financing to support R&D, inventory and sales rebuild raises execution and dilution risk and constrains long‑term reinvestment flexibility.
Material Revenue Decline And Dependence On Regulatory/execution OutcomesA sharp revenue decline and compressed gross profit reduce near‑term operating leverage. Future upside depends on regulatory approvals for GMO products and the company's ability to convert pipeline into sales; those timing and execution uncertainties create prolonged revenue unpredictability.
SEED FAQ
What was Origin Agritech Limited’s price range in the past 12 months?
Origin Agritech Limited lowest stock price was $0.91 and its highest was $2.49 in the past 12 months.
What is Origin Agritech Limited’s market cap?
Origin Agritech Limited’s market cap is $12.14M.
When is Origin Agritech Limited’s upcoming earnings report date?
Origin Agritech Limited’s upcoming earnings report date is Jan 11, 2027 which is in 160 days.
How were Origin Agritech Limited’s earnings last quarter?
Origin Agritech Limited released its earnings results on May 21, 2026. The company reported -$0.172 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.172.
Is Origin Agritech Limited overvalued?
According to Wall Street analysts Origin Agritech Limited’s price is currently Overvalued.
Does Origin Agritech Limited pay dividends?
Origin Agritech Limited does not currently pay dividends.
What is Origin Agritech Limited’s EPS estimate?
Origin Agritech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Origin Agritech Limited have?
Origin Agritech Limited has 12,144,586 shares outstanding.
What happened to Origin Agritech Limited’s price movement after its last earnings report?
Origin Agritech Limited reported an EPS of -$0.172 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Origin Agritech Limited?
Currently, no hedge funds are holding shares in SEED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Origin Agritech Limited
Established in 1997 and headquartered in Beijing, China, Origin Agritech Limited is a Chinese firm operating in two primary areas: agricultural biotechnology and an e-commerce platform. Its biotechnology segment focuses on the genetic enhancement and breeding of crop seeds, encompassing the development, production, and distribution of hybrid crop varieties and associated seed technologies. The firm also manages an e-commerce platform that caters to farmers across China, offering a diverse array of goods via online and mobile channels. This selection includes agricultural seeds like corn, rice, and vegetables, along with essential farming inputs such as fertilizers and agricultural chemicals. Additionally, the platform provides food, household items, and other consumer products. Origin Agritech maintains collaboration agreements with esteemed institutions such as the Chinese Academy of Agricultural Sciences, the National Maize Improvement Center, China Agricultural University, and Zhejiang University.
SEED Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced view: clear operational and structural progress (large cuts in G&A, improved operating loss, strengthened biotech credentials, rebuilt sales force, sizable breeding pipeline and targeted variety acquisitions) alongside meaningful near-term challenges (a 31.9% revenue decline, ongoing net loss, modest cash position, higher inventories and dependency on regulatory timing for GMO commercialization). Management emphasized that the company is in the midpoint of a recovery plan and investing in sales and R&D to convert pipeline into revenue, but realization of that upside remains contingent on execution and policy developments.View all SEED earnings summariesTechnical Analysis
American Vanguard
―
Arcadia Biosciences
―
BioHarvest Sciences
―
Bioceres Crop Solutions
―
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
0.17% Other Institutional Investors
99.76% Public Companies and
Individual Investors









